Role of nesfatin-1 in a rat model of visceral hypersensitivity

Figure 4 Effect of anti-nesfatin-1/nucleobindin-2, α-helical corticotropin releasing factor 9-41 and NBI-27914 treatment on visceral sensitivity in model rats. A: Abdominal withdrawal reflex (AWR) scores were used as an index in response to distension pressure. Model rats receiving intracerebroventricular injection of anti-nesfatin-1/nucleobindin-2 (NUCB2), α-helical corticotropin releasing factor (CRF) 9-41 and NBI-27914 showed decreased mean AWR scores compared with model rats receiving vehicle injection, at 20, 40, 60 and 80 mmHg, ^aP < 0.05 vs vehicle group, n = 8; B: Electromyographic (EMG) activity in the external oblique muscle in response to graded colorectal distension. Compared with vehicle administration, EMG activity in model rats administered intracerebroventricularly with anti-nesfatin-1/NUCB2, α-helical CRF9-41 or NBI-27914 was significantly decreased at 20, 40, 60 and 80 mmHg compared with model rats receiving vehicle injection, ^aP < 0.05 vs vehicle group, n = 8.